MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

• Status: Completed
• Trial end date: 2008-02-05
• Target enrollment: 0
• Participant gender: All

Summary

The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Pioglitazone; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patients Have Type 2 Diabetes Mellitus

• On Diet/Exercise Therapy And Pioglitazone As Monotherapy

Exclusion Criteria:

• Patients Have Type 1 Diabetes Mellitus